Collectively, the disease-linked pathologies related to FUS, hnRNP A1 and TDP-43 all highly rely on PARP-mediated nucleoplasmic transport and stress granules; therefore, agents that inhibit PARylation or PAR chain formation are therapeutic tools for ALS (Figure 4). This evidence concerns the gene PARP1 and amyotrophic lateral sclerosis.